Cargando…

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

BACKGROUND: As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL), relapse of Ph(+)ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that LPCs were enriche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Yuan, Wu, Yi-Lin, Song, Yang, Shi, Min-Min, Cao, Xie-Na, Zhao, Hong-Yan, Qin, Ya-Zhen, Lai, Yue-Yun, Jiang, Hao, Jiang, Qian, Huang, Xiao-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577751/ https://www.ncbi.nlm.nih.gov/pubmed/28854975 http://dx.doi.org/10.1186/s12967-017-1286-5

Ejemplares similares

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis
por: El-Menshawy, Nadia, et al.
Publicado: (2018)

PB1724: NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
por: LI, Yanming, et al.
Publicado: (2023)

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report
por: Lai, Binbin, et al.
Publicado: (2018)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
por: Shin, Junghoon, et al.
Publicado: (2018)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia
por: Zhang, Hailong, et al.
Publicado: (2014)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?
por: Vettenranta, Kim, et al.
Publicado: (2022)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Additional chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia
por: Tashfeen, Sunila, et al.
Publicado: (2020)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
por: Saleh, Khalil, et al.
Publicado: (2022)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL
por: Tasian, Sarah K, et al.
Publicado: (2016)

The Philadelphia chromosome in leukemogenesis
por: Kang, Zhi-Jie, et al.
Publicado: (2016)

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study
por: Nishiwaki, Satoshi, et al.
Publicado: (2023)

Primary Philadelphia chromosome positive acute myeloid leukemia: A case report
por: Shao, Xiaoyan, et al.
Publicado: (2018)

Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia
por: Park, Han-Seung
Publicado: (2020)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis
por: Haidary, Ahmed Maseh, et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kawano, Noriaki, et al.
Publicado: (2020)

A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
por: Lim, Young Tae, et al.
Publicado: (2016)

Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021)

P394: FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Zhu, Kaibo, et al.
Publicado: (2023)

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
por: Cortés, Alicia Arenas, et al.
Publicado: (2019)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Oligoclonal Immunoglobulin Gene Rearrangements in Philadelphia Chromosome‐positive Common Acute Lymphoblastic Leukemia
por: Ikeda, Takeshi, et al.
Publicado: (1990)

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
por: Soverini, Simona, et al.
Publicado: (2019)

Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Nishiwaki, Satoshi, et al.
Publicado: (2021)

The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ribera, Jose-Maria, et al.
Publicado: (2018)

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
por: Li, Shaoguang
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_u9qjepdmpsr262s4u7s5l421ge